

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## Epidemiological relationship between *Mycoplasma pneumoniae* Pneumonia and recurrent wheezing episode in children

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026461
Article Type:	Research
Date Submitted by the Author:	03-Sep-2018
Complete List of Authors:	Rhim, Jung-Woo; The Catholic University of Korea Daejeon St. Mary's Hospital Kang, Hyun-Mi; The Catholic University of Korea, Daejeon St. Mary's Hospital, Department of Pediatrics Yang, Eun-Ae; The Catholic University of Korea Daejeon St. Mary's Hospital Lee, Kyung-Yil; The Catholic University of Korea, Daejeon St Mary's Hospital, Department of Pediatrics
Keywords:	<i>Mycoplasma pneumoniae</i> pneumonia, Recurrent wheezing episode, Asthma < THORACIC MEDICINE, Epidemiology < INFECTIOUS DISEASES, children

SCHOLARONE™  
Manuscripts

Peer Review Only

1  
2  
3  
4  
5 **Epidemiological relationship between *Mycoplasma pneumoniae* Pneumonia**  
6  
7 **and recurrent wheezing episode in children**  
8  
9

10  
11  
12 Jung-Woo Rhim, Hyun-Mi Kang, Eun-Ae Yang, Kyung-Yil Lee

13  
14 Department of Pediatrics, Daejeon St. Mary's Hospital, College of Medicine, The Catholic  
15 University of Korea, Seoul, Republic of Korea.  
16  
17

18  
19  
20  
21 **Affiliations:**

22  
23 Department of Pediatrics, The Catholic University of Korea Daejeon St. Mary's Hospital,  
24 Daejeon, Republic of Korea  
25  
26

27  
28  
29  
30 **Corresponding Author:**

31 Kyung-Yil Lee, MD

32  
33 Department of Pediatrics, The Catholic University of Korea Daejeon St. Mary's Hospital, 64  
34 Daeheung-ro, Jung-gu, Daejeon 34943, Republic of Korea  
35  
36

37  
38 Tel. +82-42-220-9540, Fax. +82-42-221-2925,  
39

40 E-mail: leekyungyil@catholic.ac.kr  
41  
42  
43

44 **Word count: 2,520** (except abstract and references)  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## ABSTRACT

**Objective:** The relationship between *Mycoplasma pneumoniae* (MP) infection and initiation or exacerbation of childhood asthma remains controversial. This study was aimed to evaluate epidemiological and clinical relationship between MP infection and childhood recurrent wheezing episode (RWE).

**Design:** Retrospective case note review.

**Setting:** Paediatric department at a single Korean institution.

**Participants:** Consecutive admitted patients with MP pneumonia and RWE (0-15 years of age) between 2003 and 2014.

**Methods:** The retrospective medical records of patients with MP pneumonia (n=793 for epidemiological analysis and n=501 for clinical analysis) and those with RWE (n=384) from 2003 to 2014 were analyzed.

**Results:** During the study period, there were three MP pneumonia epidemics, but no corresponding increase of patients with RWE were seen in the epidemic years. In the 501 MP pneumonia patients, 52 (10.4%) had wheezing at presentation, 72 (14.4%) had allergic disease history, and 15 (3%) had RWE. The MP pneumonia patients with wheezing at presentation (n=52) were younger (3.7 years vs. 5.6 years,  $P<.001$ ) and were more likely to have an allergic disease history than were those without wheezing (n=449). Among the patients with wheezing at presentation, 10 patients had previously RWE history. In a follow-up study, 13 patients (including 5 RWE) with initial wheezing and 25 patients (including 2 RWE) without wheezing had wheezy episodes after discharge. Among the total 501 patients, it was estimated that at least 31 MP pneumonia patients (6.2%) showed recurrent wheezing after initial MP infection.

**Conclusions:** A small part of children with MP pneumonia showed recurrent wheezing after MP pneumonia, and patients with RWE had a greater likelihood of experiencing wheezing when they had an initial MP. However, there were no increased admitted patients with RWE

1  
2  
3  
4 in MP pneumonia epidemic periods because of rarity of MP reinfection in children including  
5 patients with RWE or asthma.

6  
7 **Key words:** asthma, children, epidemiology, *Mycoplasma pneumoniae*, pneumonia, recurrent  
8 wheezing  
9

### 10 11 12 13 **Strengths and limitations of this study**

- 14  
15 - This may be the first long-term epidemiological study regarding relationship between  
16 *Mycoplasma pneumoniae* (MP) infection and recurrent wheezing episode (RWE).  
17  
18 - Two-times examination for diagnosis of MP pneumonia strengthened accuracy for patient  
19 selection.  
20  
21 - During the study period, there were no significant changes in the diagnosis and treatment  
22 policies in our department.  
23  
24 - We discussed unsolved issues regarding MP infection and childhood asthma.  
25  
26 - There were limitations in this study in regards to the following: retrospective analysis, data  
27 collected from a single centre, and patient selection under our definition of recurrent  
28 wheezing episode (childhood asthma).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

*Mycoplasma pneumoniae* (MP) is one of the major pathogens in respiratory tract infections in children and young adults, manifesting from asymptomatic infection to potential fatal pneumonia. MP pneumonia is an endemic disease in large communities, but it occurs in regional cyclic epidemics of 3-7 year intervals. Also, MP is associated with a wide spectrum of other organ-specific diseases including neurologic, dermatologic, hepatic, cardiac, musculoskeletal, hematologic diseases and possibly bronchial asthma.<sup>1,2</sup>

Childhood asthma is a complex disease process that can be classified into heterogeneous clinical phenotypes.<sup>3</sup> The diverse phenotypes of childhood asthma may be associated with host factors, including the developing immune and respiratory systems and individual genetic variations. Childhood asthma is also influenced by environmental factors such as socio-economic and/or cultural differences across populations.<sup>3,4</sup> Therefore, diagnosis of asthma in children, especially in children under 5 years of age, could not be defined definitely, and the phenotypes of childhood asthma, such as the prevalence of asthma and frequency of severe asthma, could differ among populations.<sup>5,6</sup> It has been suggested that initiation of asthma and acute exacerbation of asthma are associated with a variety of respiratory pathogens, including respiratory syncytial viruses (RSV), rhinoviruses and MP, although the exact reasons are still not fully understood.<sup>7-9</sup> In addition, it has been suggested that chronic MP infection is related to persistent bronchial hyper-responsiveness, chronic inflammation, and acute exacerbation in adult and child asthmatics.<sup>10-13</sup>

In Korea, MP pneumonia epidemics have been observed every 3 to 4 years from the mid-1980s to present. We recently found that during 2003-2012, there were three nationwide MP pneumonia epidemics, all of which had similar epidemiological patterns including age distribution and seasonal pattern.<sup>14</sup> In this study, we evaluated the epidemiological and clinical characteristics of patients with MP pneumonia and those with recurrent wheezing

1  
2  
3  
4 episode (RWE) admitted during the 2003-2014 period, and we compared the data in both  
5  
6 diseases. Also, we discussed the relationship between MP infection and childhood asthma.  
7  
8  
9

## 10 **METHODS**

### 11 **Study design and setting**

12  
13 This study was a retrospective study conducted at Department of Paediatrics, The Catholic  
14  
15 University of Korea Daejeon St. Mary's Hospital, a secondary referral hospital performing  
16  
17 primary care for patients with MP pneumonia or RWE.  
18  
19  
20

### 21 **Patients and data collection**

22  
23 We performed a retrospective analysis of medical records of patients with MP pneumonia or  
24  
25 RWE who were admitted to The Catholic University of Korea Daejeon St. Mary's Hospital  
26  
27 from January 2003 to December 2014. In this study, diagnosis of MP pneumonia was based  
28  
29 on chest radiographic findings and 2-times titration of IgM antibody (Serodia-Myco II,  
30  
31 Fujirebio Inc., Tokyo, Japan; positive cutoff value  $\geq 1:40$ ) at presentation and before  
32  
33 discharge, as previously described.<sup>14,15</sup> The subjects with RWE were collected through the  
34  
35 diagnostic code number J459 (asthma, asthma nature, bronchial asthma, and infantile asthma).  
36  
37 However, we used the term RWE in this study, because majority of patients were under 5  
38  
39 years of age and some patients over 6 years of age did not perform confirmative study for  
40  
41 asthma such as pulmonary function test. An RWE patient was defined as one with expiratory  
42  
43 wheezing at admission with at least one or more wheezing episodes within 6 months before  
44  
45 admission, regardless of patient's age, and 37 cases of <2 years of age were included in the  
46  
47 present study. Patients with first wheezing at admission for any respiratory tract infection,  
48  
49 including MP pneumonia, were excluded from the RWE group. Readmitted patients with  
50  
51 RWE in the same year or different year were included in this series (35 episodes). Clinical  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 and laboratory parameters were evaluated and compared between the groups. After discharge,  
5  
6 wheezing episodes were evaluated through the medical records in both patient groups who  
7  
8 revisited the outpatient clinic or had readmission at least two or more times from the date of  
9  
10 discharge to December 2014.  
11

### 12 13 14 15 **Statistical analysis**

16 All calculations were performed with SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA).  
17  
18 Comparisons between groups were performed using the Student's t-test, chi-square test, and  
19  
20 Fisher's exact test, and the data were expressed as mean  $\pm$  standard deviation (SD) for  
21  
22 continuous variables. A *P* value of  $<0.05$  was considered statistically significant.  
23  
24  
25  
26  
27

## 28 **RESULTS**

29  
30 The subjects in the present study were 793 patients with MP pneumonia and 384 patients  
31  
32 with RWE during the study period. For epidemiological comparison, a total 793 patients were  
33  
34 used, as shown in previously published article.<sup>14</sup> For clinical comparison between the groups,  
35  
36 a total of 501 MP pneumonia patients that were admitted during the recent epidemics (241  
37  
38 cases in 2007-2006, and 260 cases in 2011), and 384 patients with RWE were analyzed (Fig.  
39  
40 1). Most of MP pneumonia patients had follow-up period at least 3 years from last epidemic  
41  
42 year of 2011, but the follow-up subjects satisfied with our selection criteria were 180 among  
43  
44 501 cases in the MP pneumonia group and 206 among 384 cases in the RWE group.  
45  
46  
47  
48  
49

### 50 **Epidemiological data of MP pneumonia and RWE from 2003 to 2014**

51  
52 In MP pneumonia patients, there were clear outbreaks of cases in 2003, 2006-2007, and  
53  
54 2011, with a few cases occurring in the inter-epidemic periods. There were relatively steady  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 numbers of RWE cases every year during the study period. There were no corresponding  
5  
6 increased cases in MP pneumonia epidemic years except in 2007 (Fig. 2). No MP pneumonia  
7  
8 patient who was re-admitted due to MP reinfection across the epidemics was observed during  
9  
10 study period. The mean age and age distribution were similar, and the peak age groups were  
11  
12 2-5 years of age in both groups (Fig. 3). In seasonality of both groups, MP pneumonia was  
13  
14 prevalent in decreasing order of autumn, summer, winter, and spring, while patients with  
15  
16 RWE were most prevalent in autumn, followed by spring, winter, and summer (Fig. 4).  
17  
18  
19  
20

### 21 **Demographic and clinical characteristics of MP pneumonia and RWE groups**

22  
23 Demographic and clinical data in both groups are shown in Table 1. The mean age and age  
24  
25 distribution were similar in both groups as shown in Fig. 2 (5.4 years vs. 5.6 years,  $P =$   
26  
27 0.312). Both groups had male predominance, and there were more males in the RWE group.  
28  
29 As expected, cases with wheezing at presentation, the proportion of patients with past history  
30  
31 or family history of allergic diseases, and past history of wheezing were higher in the RWE  
32  
33 group. Recurrent wheezing after discharge was observed in 38 of 180 patients with MP  
34  
35 pneumonia and 141 of the 206 patients with RWE ( $P < 0.001$ ). In laboratory indices, WBC  
36  
37 count, eosinophil differential, IgG, and IgE were higher in the RWE group (Table 1).  
38  
39

40  
41 In MP pneumonia patients, 52 of the total 501 patients (10.4%) had wheezing at  
42  
43 presentation, 72 (14.4%) had a past history of allergic diseases, 15 (3%) had RWE according  
44  
45 to our definition, and 40 (8%) had a family history of allergic diseases. When we divided the  
46  
47 MP pneumonia patients into two groups of patients with wheezing ( $n=52$ ) and without  
48  
49 wheezing ( $n=449$ ), the patients with wheezing were younger (3.7 years vs. 5.6 years,  $P <$   
50  
51 0.001) and had higher proportions of past history allergic diseases and wheezing history and  
52  
53 higher values of leukocyte count and eosinophil differential (Table 2). Among the 52 MP  
54  
55 pneumonia patients with wheezing at admission, 10 were patient with RWE, while 42 had no  
56  
57

1  
2  
3  
4 previous RWE history. Thus, in this study, 66% (10 of 15) of patients with RWE history  
5  
6 presented with wheezing, while 8.6% of patients without RWE history (42 of 486) were  
7  
8 wheezing at presentation. In a follow-up study of patients who visited two or more times after  
9  
10 discharge, 13 (including 5 cases of RWE) of 21 MP pneumonia patients with initial wheezing  
11  
12 and 25 (including 2 cases of RWE) of 159 MP pneumonia patients without wheezing had at  
13  
14 least one wheezing episode after discharge (Table 2). Although not all patients were  
15  
16 followed-up, it was estimated that at least 31 of the total MP pneumonia patients (n=501,  
17  
18 6.2%) showed a recurrent wheezing after initial MP infection.  
19  
20  
21  
22

## 23 **DISCUSSION**

24  
25  
26 In this study, we found that patients with MP pneumonia and patients with RWE had a  
27  
28 similar mean age and age distribution during the past decade. However, the annual number of  
29  
30 cases in the two groups was quite different; there were relatively stable number of annual  
31  
32 cases in patients with RWE, without a corresponding increase in cases during or after MP  
33  
34 pneumonia epidemic years. Although reinfection with MP reported to be not uncommon in  
35  
36 other studies based on polymerase chain reaction (PCR) or single serologic test-based  
37  
38 studies,<sup>16</sup> we found that there were no serologically confirmed reinfected MP pneumonia  
39  
40 patients among 793 patients during study period, except a few readmitted patients with  
41  
42 complications of initial MP infection in each epidemic. It suggests that reattack of MP  
43  
44 pneumonia in children is extremely rare, and once infected children seem to have immunity  
45  
46 to other MP strains in future epidemics including macrolide-resistant MP strains.<sup>14</sup> During a  
47  
48 MP epidemic, majority of susceptible children are asymptomatic or mild symptoms such as  
49  
50 fever and sore throat, and only a small part of MP infected patients may affect pneumonia.<sup>1,2</sup>  
51  
52  
53 Moreover, since MP reinfection is also rare in asthmatics of all age, our epidemiological data  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 might not be associated with the situations where asthmatics have reasons for increase of  
5 admission such as exacerbation or initiation of RWE or asthma.  
6  
7

8 MP pneumonia patients in this study showed a similar prevalence of allergic diseases  
9 compared to data from previous nationwide questionnaire-based studies in Korea: 3%  
10 (15/501) and 14.4% (72/501) of MP pneumonia patients had a past history of RWE (asthma)  
11 and a past history of allergic diseases, respectively. Whereas 5.8% of 6- to 7-year-old school  
12 children had asthma history in 2000, and 13.5% of children reported a diagnosis of atopic  
13 dermatitis in 2008-2011 in Korea.<sup>17,18</sup> In this study, among 52 MP pneumonia patients with  
14 initial wheezing, 10 were patients with RWE, while 42 had no previous wheezing history.  
15 Therefore, 66.6% (10 of 15) of patients with RWE, and 8.6% (42 of 486) of patients without  
16 RWE history were wheezing, and it suggests that patients with RWE or asthma with first-  
17 time MP infection might be prone to a wheezing episode as well as other respiratory virus  
18 infections as compounding factors of asthma exacerbation. Also, we found that after MP  
19 infection, at least 6% of MP pneumonia patients showed subsequent wheezing during at least  
20 over 3 years after initial MP infection. A large proportion of patients who experienced lower  
21 respiratory infections caused by RSV and rhinoviruses were reported to show recurrent  
22 wheezing after initial infection, especially when they were infected with other respiratory  
23 agents.<sup>19,20</sup> A study reported that approximately 50% of children affected with severe RSV  
24 bronchiolitis had a subsequent asthma diagnosis.<sup>19</sup> In Korea, the prevalent age in these  
25 respiratory viral infections are younger than that in MP infection, and it is possible that  
26 majority of MP infected patients experience RSV infection prior to MP infection as well as in  
27 other populations. On the other hand, some patients with severe MP pneumonia had  
28 prolonged anatomical abnormalities, suggestive of small airway obstruction,<sup>21</sup> and some  
29 patients had reduced pulmonary function after MP infection.<sup>8</sup> Thus, patients with severe lung  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 injury caused by any respiratory pathogens may be prone to recurrent wheezing and  
5  
6 subsequent diagnosis of asthma.  
7

8 We found that WBC count, eosinophil differential, IgG, and IgE were higher in the RWE  
9  
10 group than those in the MP pneumonia group which had similar mean age. It could in part be  
11  
12 explained that different activation of immune system of the host against the insults from  
13  
14 RWE which induces chronic or repeated inflammation may be reflected in these laboratory  
15  
16 findings.  
17

18  
19 Previous studies have reported that asthma patients are more likely to be infected or  
20  
21 colonized with MP compared to healthy controls, and MP infection in chronic asthmatics  
22  
23 might be associated with persistent bronchial hyper-responsiveness and exacerbation.<sup>10-13</sup> MP  
24  
25 pneumonia epidemics are cyclic in 3-4-year intervals, and the duration of an epidemic is  
26  
27 generally limited to 1 year or occasionally 2 years, and during the inter-epidemic period of  
28  
29 the 2-3 years there are a few patients as observed in this study.<sup>14</sup> There are many  
30  
31 asymptomatic healthy MP carriers during the epidemic periods, especially young children,  
32  
33 who may serve as reservoirs for the spread of MP infection.<sup>22-24</sup> It is natural that colonization  
34  
35 of MP during MP pneumonia epidemics can occur in asthma patients and old persons as well  
36  
37 as in healthy young children and adults since colonization does not mean the 'infection'. The  
38  
39 prevalent rates of MP colonization between the asthma group and the control groups could be  
40  
41 influenced by the MP epidemic year during the study period. Thus, patient selection bias  
42  
43 could be considered if a study period is long and different in the both groups. Wood et al.  
44  
45 reported that the rates of MP colonization in asthmatics and healthy children during the same  
46  
47 study period were similar using a sensitive PCR method,<sup>13</sup> suggesting that colonization occurs  
48  
49 equally in the two groups. One study reported that the status of asthma control and the lung  
50  
51 function tests were not different between asthmatic patients with chronic MP infection and  
52  
53 those without, indicating the similar severity of asthma between the group.<sup>25</sup>  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 In this study, the numbers of patient with RWE during a recent decade did not change with  
5  
6 a rather decreasing trend in recent years. Moreover, we have experienced that asthma severity  
7  
8 might change to a milder phenotype in Korea over time. A recent population-based study in  
9  
10 Korea also indicated that the prevalence of asthma was reduced in recent years.<sup>26</sup> Changing  
11  
12 epidemiology in infectious disease and infection-related immune-mediated diseases,  
13  
14 including scarlet fever, pandemic influenza, acute rheumatic fever, acute post-streptococcal  
15  
16 glomerulonephritis, and Kawasaki disease, has been well documented in Korea; initially  
17  
18 severe disease phenotypes have changed to milder phenotypes over time.<sup>27-30</sup> Because allergic  
19  
20 diseases, including asthma, may be associated with various pathogen infections and  
21  
22 environmental factors,<sup>31,32</sup> it is possible that the changing epidemiology of childhood asthma  
23  
24 occurs over time in the populations.  
25  
26

27  
28 There are some limitations to this retrospective study. We evaluated only admitted patient  
29  
30 groups with a part of the follow-up subjects at a single hospital. History of allergic diseases  
31  
32 was not as precise as in International Study of Asthma and Allergies in Childhood (ISAAC)  
33  
34 studies. In our definition of RWE in the present study, the pneumonia patients with first  
35  
36 wheezing, regardless of severity of respiratory symptoms, were not included in the asthma  
37  
38 group. Considering the age distribution of patients, larger part of patients might be the  
39  
40 transient recurrent wheezers and small part of true asthma patients who experience and  
41  
42 progress recurrent wheezing into adulthood might be included in the RWE group. Further  
43  
44 multicenter studies with prospective designs are needed for exact epidemiological  
45  
46 relationship between MP infection and childhood asthma.  
47  
48  
49  
50

## 51 CONCLUSIONS

52  
53 A small part of MP pneumonia patients had a subsequent wheezing after initial MP infection  
54  
55 as well as those observed in other respiratory pathogen infections. Patients with RWE have a  
56  
57

1  
2  
3  
4 greater likelihood of experiencing wheezing than non-asthmatics when they had an initial MP  
5  
6 infection, suggesting that MP infection is one of exacerbation factors in childhood asthma.  
7  
8 However, we found no corresponding increase in the number of patients with RWE in MP  
9  
10 pneumonia epidemic periods, and this finding may in part be explained that MP reinfection  
11  
12 are very rare in children including patients with RWE or asthma as shown in this study.  
13  
14  
15

### 16 17 **Acknowledgements**

18  
19 The authors thank Drs. Eun-Kyung Kim, Sung-Churl Lee and other colleagues for help in  
20  
21 data collection during study period.  
22

### 23 24 **Contributors**

25  
26 KYL designed and conceptualized and the study, and drafted the manuscript. JUR  
27  
28 participated in preliminary data collection, and wrote the initial manuscript. HMK and EAY  
29  
30 analyzed data and revised the manuscript for critical content. All authors approved the final  
31  
32 manuscript as submitted and agree to be accountable for all aspects of the work.  
33

### 34 35 **Funding statement**

36  
37 This research received no specific grant from any funding agency in the public, commercial  
38  
39 or not-for-profit sectors.  
40

### 41 42 **Competing interests**

43  
44 None declared.

### 45 46 **Ethic approval**

47  
48 The study was approved by the Institutional Review Board of The Catholic University of  
49  
50 Korea Daejeon St. Mary's Hospital (DC17RESI0053).

### 51 52 **Data sharing statement**

53  
54 Data of the study are available from the corresponding author (KYL).  
55  
56  
57

## REFERENCES

1. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of *Mycoplasma pneumoniae* infections. *FEMS Microbiol Rev* 2008;32:956-73.
2. Lee KY. Pediatric respiratory infections by *Mycoplasma pneumoniae*. *Expert Rev Anti Infect Ther* 2008;6:509-21.
3. Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from an epidemiological approach. *Paediatr Respir Rev* 2004;5:155-61.
4. Strina A, Barreto ML, Cooper PJ, *et al*. Risk factors for non-atopic asthma/wheeze in children and adolescents: a systematic review. *Emerg Themes Epidemiol* 2014;11:5.
5. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998;351:1225-32.
6. Asher MI, Montefort S, Björkstén B, *et al*; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 2006;368:733-43.
7. Johnston SL, Pattemore PK, Sanderson G, *et al*. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995;310:1225-9.
8. Biscardi S, Lorrot M, Marc E, *et al*. *Mycoplasma pneumoniae* and asthma in children. *Clin Infect Dis* 2004;38:1341-6.
9. Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of asthma. *Expert Rev Respir Med* 2010;4:71-83.
10. Kraft M, Cassell GH, Henson JE, *et al*. Detection of *Mycoplasma pneumoniae* in the airways of adults with chronic asthma. *Am J Respir Crit Care Med* 1998;158:998-1001.

11. Sutherland ER, King TS, Icitovic N, *et al*; National Heart, Lung and Blood Institute's Asthma Clinical Research Network. A trial of clarithromycin for the treatment of suboptimally controlled asthma. *J Allergy Clin Immunol* 2010;126:747-53.
12. Varshney AK, Chaudhry R, Saharan S, *et al*. Association of *Mycoplasma pneumoniae* and asthma among Indian children. *FEMS Immunol Med Microbiol* 2009;56:25-31.
13. Wood PR, Hill VL, Burks ML, *et al*. *Mycoplasma pneumoniae* in children with acute and refractory asthma. *Ann Allergy Asthma Immunol* 2013;110:328-34.
14. Kim EK, Youn YS, Rhim JW, *et al*. Epidemiological comparison of three *Mycoplasma pneumoniae* pneumonia epidemics in a single hospital over 10 years. *Korean J Pediatr* 2015;58:172-7.
15. Lee SC, Youn YS, Rhim JW, *et al*. Early serologic diagnosis of *Mycoplasma pneumoniae* pneumonia: an observational study on changes in titers of specific-IgM antibodies and cold agglutinins. *Medicine* 2016;95:e3605.
16. Papaetis GS, Anastasakou E, Tselou T, *et al*. Serological evidence of *Mycoplasma pneumoniae* infection in patients with acute exacerbation of COPD: analysis of 100 hospitalizations. *Adv Med Sci* 2010;55:235-241.
17. Lee SI. Prevalence of childhood asthma in Korea: international study of asthma and allergies in childhood. *Allergy Asthma Immunol Res* 2010;2:61-4.
18. Lee JH, Han KD, Kim KM, *et al*. Prevalence of atopic dermatitis in Korean children based on data from the 2008-2011 Korean National Health and Nutrition Examination Survey. *Allergy Asthma Immunol Res* 2016;8:79-83.
19. Bacharier LB, Cohen R, Schweiger T, *et al*. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. *J Allergy Clin Immunol* 2012;130:91-100.



- 1  
2  
3  
4 20. Jackson DJ, Gangnon RE, Evans MD, *et al.* Wheezing rhinovirus illnesses in early life  
5 predict asthma development in high-risk children. *Am J Respir Crit Care Med*  
6 2008;178:667-72.  
7  
8  
9  
10 21. Kim CK, Chung CY, Kim JS, Kim *et al.* Late abnormal findings on high-resolution  
11 computed tomography after *Mycoplasma pneumoniae*. *Pediatrics* 2000;105:372-378.  
12  
13 22. Gnarp J, Lundback A, Sundelof B, *et al.* Prevalence of *Mycoplasma pneumoniae* in  
14 subjectively healthy individuals. *Scand J Infect Dis* 1992;24:161-4.  
15  
16 23. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, *et al.* Results of molecular detection of  
17 *Mycoplasma pneumoniae* among patients with acute respiratory infection and in their  
18 household contacts reveals children as human reservoirs. *J Infect Dis* 2001;183:675-8.  
19  
20 24. Spuesens EB, Fraaij PL, Visser EG, *et al.* Carriage of *Mycoplasma pneumoniae*  
21 in the upper respiratory tract of symptomatic and asymptomatic children: an  
22 observational study. *PLoS Med* 2013;10:e1001444.  
23  
24 25. Ansarin K, Abedi S, Ghotaslou R, *et al.* Infection with *Mycoplasma pneumoniae* is not  
25 related to asthma control, asthma severity, and location of airway obstruction. *Int J Gen*  
26 *Med* 2010;4:1-4.  
27  
28 26. Kim BK, Kim JY, Kang MK, *et al.* Allergies are still on the rise? A 6-year nationwide  
29 population-based study in Korea. *Allergol Int* 2016;65:186-91.  
30  
31 27. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever,  
32 streptococcal disease, and scarlet fever: the decline of rheumatic fever. *Rev Infect Dis*  
33 1989;11:928-53.  
34  
35 28. Rhim JW, Go EJ, Lee KY, *et al.* Pandemic2009 H1N1 virus infection in children and  
36 adults: A cohort study at a single hospital throughout the epidemic. *Int Arch Med*  
37 2012;5:13.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 29. Keum SW, Hur SM, Youn YS, *et al.* Changes in acute poststreptococcal  
5  
6 glomerulonephritis: an observation study at a single Korean hospital over two decades.  
7  
8 *Child Kidney Dis* 2015;19:112-7.  
9
- 10 30. Kil HR, Yu JW, Lee SC, *et al.* Changes in clinical and laboratory features of Kawasaki  
11  
12 disease noted over time in Daejeon, Korea. *Pediatr Rheumatol* 2017;15:60.  
13
- 14 31. Atkinson TP. Is asthma an infectious disease? New evidence. *Curr Allergy Asthma Rep*  
15  
16 2013;13:702-9.  
17
- 18 32. Hossaini RF, Ghaffari J, Ranjbar A, *et al.* Infections in children with asthma. *J Pediatr*  
19  
20 *Rev* 2013;1:25-36.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Clinical and laboratory findings of the patients with MP pneumonia or recurrent wheezing episode (RWE)**

	MP pneumonia (n = 501)	RWE (n = 384)	<i>P</i>
<b>Clinical characteristics</b>			
Age (y)	5.4 ± 3.4	5.6 ± 3.5	0.31
Male : female	255/246	156/128	<.001
Wheeze at presentation, n (%)	52 (10.4)	384 (100)	<.001
Past history of allergy*, n (%)	72 (14.4)	379 (98.7)	<.001
Past history of wheeze, n (%)	15 (3.0)	384 (100)	<.001
Family history of allergy, n (%)	40 (8.0)	134 (34.9)	<.001
Wheeze after discharge, n (%)	38/180 (21.1)	141/206 (68.4)	<.001
<b>Laboratory findings</b>			
Leukocyte (/μL)	8800 ± 4500	11100 ± 4200	<.001
Eosinophil (%)	2.2 ± 2.9	3.8 ± 3.9	<.001
IgG (mg/dL)	899 ± 235	946 ± 232	<.001
IgE (IU/mL)	267 ± 391	617 ± 673	<.001

\* Number of patients who had history to be diagnosed as having asthma, allergic rhinitis, and/or atopic dermatitis

**Table 2. Clinical and laboratory findings of MP pneumonia patients with wheezing and without wheezing**

	Wheezing (n = 52)	No Wheezing (n = 449)	<i>P</i>
Clinical characteristics			
Age (y)	3.7 ± 3.0	5.6 ± 3.4	<.001
Male : female	32/20	223/226	0.11
Past history of allergy*, n (%)	16 (30.8)	56 (12.5)	0.01
Past history of wheeze, n (%)	10 (19.2)	5 (1.1)	<.001
Family history of allergy, n (%)	8 (15.4)	32 (7.1)	0.05
Wheeze after discharge, n (%)	13/21 (61.9)	25/159 (15.7)	<.001
Laboratory findings			
Leukocyte (x10 <sup>3</sup> //μL)	10400 ± 5400	8700 ± 4.3	0.03
Eosinophil (%)	3.0 ± 3.2	2.1 ± 2.9	0.08
IgG	873 ± 219	903 ± 238	0.43
IgE	407 ± 609	249 ± 350	0.11

\* Number of patients who had history to be diagnosed as having asthma, allergic rhinitis, and/or atopic dermatitis

**Figure legends**

Figure 1. Flow diagram of the patient selection in this study

Figure 2. Annual cases of MP pneumonia and recurrent wheezing episode during 2003-2014

Figure 3. Age distribution in MP pneumonia and recurrent wheezing episode groups

Figure 4. Seasonality in MP pneumonia and recurrent wheezing episode groups

For peer review only




Fig. 1. Flow diagram of the patient selection in this study

254x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 2. Annual cases of MP pneumonia and recurrent wheezing episode during 2003-2014  
254x190mm (96 x 96 DPI)




Fig. 3. Age distribution in MP pneumonia and recurrent wheezing episode groups

254x190mm (96 x 96 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 4. Seasonality in MP pneumonia and recurrent wheezing episode groups  
254x190mm (96 x 96 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4
Objectives	3	State specific objectives, including any pre-specified hypotheses	P4-5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	P5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	P5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P5
Bias	9	Describe any efforts to address potential sources of bias	P5
Study size	10	Explain how the study size was arrived at	P5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P6
		(b) Describe any methods used to examine subgroups and interactions	P6
		(c) Explain how missing data were addressed	-
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	-

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P6
		(b) Give reasons for non-participation at each stage	P6
		(c) Consider use of a flow diagram	P6 (figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P6
		(b) Indicate number of participants with missing data for each variable of interest	P8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	P8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	-
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	P6-8-
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	-
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P6-8
		(b) Report category boundaries when continuous variables were categorized	P6-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	P8-9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	P8-11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Epidemiological relationship between *Mycoplasma pneumoniae* Pneumonia and recurrent wheezing episode in children: an observational study at a single hospital in Korea

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026461.R1
Article Type:	Research
Date Submitted by the Author:	28-Nov-2018
Complete List of Authors:	Rhim, Jung-Woo; The Catholic University of Korea Daejeon St. Mary's Hospital Kang, Hyun-Mi; The Catholic University of Korea, Daejeon St. Mary's Hospital, Department of Pediatrics Yang, Eun-Ae; The Catholic University of Korea Daejeon St. Mary's Hospital Lee, Kyung-Yil; The Catholic University of Korea, Daejeon St Mary's Hospital, Department of Pediatrics
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Immunology (including allergy), Paediatrics
Keywords:	<i>Mycoplasma pneumoniae</i> pneumonia, Recurrent wheezing episode, Asthma < THORACIC MEDICINE, Epidemiology < INFECTIOUS DISEASES, children

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5 **Epidemiological relationship between *Mycoplasma pneumoniae* Pneumonia**  
6  
7  
8 **and recurrent wheezing episode in children: an observational study at a**  
9  
10  
11 **single hospital in Korea**  
12  
13  
14  
15

16 Jung-Woo Rhim, Hyun-Mi Kang, Eun-Ae Yang, Kyung-Yil Lee

17  
18 Department of Pediatrics, Daejeon St. Mary's Hospital, College of Medicine, The Catholic  
19  
20 University of Korea, Seoul, Republic of Korea.  
21  
22

23  
24  
25 **Affiliations:**

26  
27 Department of Pediatrics, The Catholic University of Korea Daejeon St. Mary's Hospital,  
28  
29 Daejeon, Republic of Korea  
30  
31

32  
33  
34 **Corresponding Author:**

35  
36 Kyung-Yil Lee, MD

37  
38 Department of Pediatrics, The Catholic University of Korea Daejeon St. Mary's Hospital, 64  
39  
40 Daeheung-ro, Jung-gu, Daejeon 34943, Republic of Korea

41  
42  
43 Tel. +82-42-220-9540, Fax. +82-42-221-2925,

44  
45  
46 E-mail: leekyungyil@catholic.ac.kr  
47  
48  
49

50 **Word count: 2,550** (except abstract and references)  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** This study was aimed to evaluate epidemiological and clinical relationship between MP infection and childhood recurrent wheezing episode (RWE).

**Design:** Retrospective case note review.

**Setting:** Paediatric department at a single Korean institution.

**Participants:** Consecutive admitted patients with MP pneumonia and RWE (0-15 years of age) between 2003 and 2014.

**Methods:** The retrospective medical records of patients with MP pneumonia (n=793 for epidemiological analysis and n=501 for clinical analysis) and those with RWE (n=384) from 2003 to 2014 were analyzed. Diagnosis of MP pneumonia was made based on 2-times titration of IgM antibody during hospitalization. An RWE patient was defined as one with expiratory wheezing with at least one or more wheezing episodes based on medical records.

**Results:** During 3 MP pneumonia epidemics, there were no corresponding increases of patients with RWE in the epidemic years. In the 501 MP pneumonia patients, 52 (10.4%) had wheezing at presentation and 15 (3%) had RWE. The MP pneumonia patients with wheezing at presentation (n=52) were younger and were more likely to have an allergic disease history than those without wheezing (n=449). Among wheezing patients at presentation, 10 patients had previously RWE history. In a follow-up study, 13 patients (including 5 RWE) with initial wheezing and 25 patients (including 2 RWE) without wheezing had wheezy episodes after discharge. Among the total 501 patients, it was estimated that at least 31 MP pneumonia patients (6.2%) showed recurrent wheezing after initial MP infection.

**Conclusions:** A small part of children with MP pneumonia showed recurrent wheezing after MP pneumonia, and patients with RWE had a greater likelihood of experiencing wheezing when they had an initial MP infection. However, there were no increased admitted patients with RWE in MP pneumonia epidemic periods because of rarity of MP reinfection in children including patients with RWE or asthma.

1  
2  
3  
4 **Key words:** asthma, children, epidemiology, *Mycoplasma pneumoniae* pneumonia, recurrent  
5  
6 wheezing  
7  
8  
9

10  
11 **Strengths and limitations of this study**  
12

- 13 - This may be the first long-term epidemiological study regarding relationship between  
14  
15 *Mycoplasma pneumoniae* (MP) infection and recurrent wheezing episode (RWE).  
16  
17 - Two-times examination of anti-MP IgM for diagnosis of MP pneumonia strengthened  
18  
19 accuracy for patient selection.  
20  
21  
22 - We discussed unsolved issues regarding MP infection and childhood asthma.  
23  
24 - There were limitations in this study in regards to the following: retrospective analysis, data  
25  
26 collected from a single centre, and patient selection under our definition of RWE (or  
27  
28 childhood asthma).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

*Mycoplasma pneumoniae* (MP) is one of the major pathogens in respiratory tract infections in children and young adults, manifesting from asymptomatic infection to potential fatal pneumonia. MP pneumonia is an endemic disease in large communities, but it occurs in nationwide cyclic epidemics of 3-7 year intervals. Also, MP is associated with a wide spectrum of other organ-specific diseases including neurologic, dermatologic, hepatic, cardiac, musculoskeletal, hematologic diseases and possibly bronchial asthma.<sup>1,2</sup>

Childhood asthma is a complex disease process that can be classified into heterogeneous clinical phenotypes.<sup>3</sup> The diverse phenotypes of childhood asthma may be associated with host factors, including the developing immune and respiratory systems and individual genetic variations. Childhood asthma is also influenced by environmental factors such as socio-economic and/or cultural differences across populations.<sup>3,4</sup> Therefore, diagnosis of asthma in children, especially in children under 5 years of age, could not be defined definitely, and the phenotypes of childhood asthma, such as the prevalence of asthma and frequency of severe asthma, could differ among populations.<sup>5,6</sup> It has been suggested that initiation of asthma and acute exacerbation of asthma are associated with a variety of respiratory pathogens, including respiratory syncytial viruses (RSV), rhinoviruses and MP, although the exact reasons are still not fully understood.<sup>7-9</sup> In addition, it has been suggested that chronic MP infection is related to persistent bronchial hyper-responsiveness, chronic inflammation, and acute exacerbation in children and adults with asthma.<sup>10-13</sup>

In Korea, MP pneumonia epidemics have been observed every 3 to 4 years from the mid-1980s to present. We recently found that during 2003-2012, there were three nationwide MP pneumonia epidemics, all of which had similar epidemiological patterns including age distribution and seasonal pattern.<sup>14</sup> In this study, we evaluated the epidemiological and clinical characteristics of patients with MP pneumonia and those with recurrent wheezing



1  
2  
3  
4 episode (RWE) admitted during the 2003-2014 period, and we compared the data in both  
5  
6 diseases. Also, we discussed the relationship between MP infection and childhood asthma.  
7  
8  
9

## 10 11 **METHODS**

### 12 13 14 **Study design and setting**

15  
16 This study was a retrospective study conducted at Department of Paediatrics, The Catholic  
17  
18 University of Korea Daejeon St. Mary's Hospital, a secondary referral hospital performing  
19  
20 primary care for patients with MP pneumonia or RWE.  
21  
22

### 23 24 **Patients and public involvement**

25  
26 Patients and public were not involved in the study due to its retrospective nature.  
27

### 28 29 **Patients and data collection**

30  
31 We performed a retrospective analysis of medical records of patients with MP pneumonia or  
32  
33 RWE who were admitted to our institution from January 2003 to December 2014. In this  
34  
35 study, diagnosis of MP pneumonia was based on chest radiographic findings and 2-times  
36  
37 titration of IgM antibody (Serodia-Myco II, Fujirebio Inc., Tokyo, Japan; positive cutoff  
38  
39 value  $\geq 1:40$ ) at presentation and before discharge. Briefly, diagnoses of MP pneumonia were  
40  
41 made when patients showed seroconversion (negative to positive), 4-fold or greater increase in IgM  
42  
43 titres, or high titres of  $> 1:640$  in initial and follow up examinations during the disease course.  
44  
45

46  
47 Patients who received the test once or those who did not increase or decreased titres were excluded  
48  
49 when initial titres were  $< 1:320$ .<sup>14,15</sup>  
50

51  
52 The subjects with RWE were collected through the diagnostic code number J459 (asthma,  
53  
54 asthma nature, bronchial asthma, and infantile asthma). However, we used the term RWE in  
55  
56 this study, because majority of patients were under 5 years of age and some patients over 6  
57  
58 years of age did not perform confirmative study for asthma such as pulmonary function test.  
59  
60 An RWE patient was defined as one with expiratory wheezing at admission with at least one

1  
2  
3  
4 or more wheezing episodes within 6 months before admission, regardless of patient's age  
5  
6 based on the medical records. Patients with first wheezing at admission for any respiratory  
7  
8 tract infection, including MP pneumonia, were excluded from the RWE group. Readmitted  
9  
10 patients with RWE in the same year or different year were included in this series (35  
11  
12 episodes). Clinical and laboratory parameters were evaluated and compared between the  
13  
14 groups. After discharge, wheezing episodes were evaluated through the medical records in  
15  
16 both patient groups who revisited the outpatient clinic or had readmission at least two or  
17  
18 more times from the date of discharge to December 2014.  
19  
20  
21

### 22 23 **Statistical analysis**

24  
25 All calculations were performed with SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA).  
26  
27 Comparisons between groups were performed using the Student's t-test, chi-square test, and  
28  
29 Fisher's exact test, and the data were expressed as mean  $\pm$  standard deviation (SD) for  
30  
31 continuous variables. A *P* value of  $<0.05$  was considered statistically significant.  
32  
33  
34  
35  
36

## 37 38 **RESULTS**

39  
40 The subjects in the present study were 793 patients with MP pneumonia and 384 patients  
41  
42 with RWE during the study period. For epidemiological comparison, a total 793 patients were  
43  
44 used, as shown in previously published article.<sup>14</sup> For clinical comparison between the groups,  
45  
46 a total of 501 MP pneumonia patients that were admitted during the recent epidemics (241  
47  
48 cases in 2007-2006, and 260 cases in 2011), and 384 patients with RWE were analyzed (Fig.  
49  
50 1). Most of MP pneumonia patients had follow-up period at least 3 years from last epidemic  
51  
52 year of 2011, but the follow-up subjects satisfied with our selection criteria were 180 among  
53  
54 501 cases in the MP pneumonia group and 206 among 384 cases in the RWE group.  
55  
56  
57

### 58 59 **Epidemiological data of MP pneumonia and RWE from 2003 to 2014**

60

1  
2  
3  
4 In MP pneumonia patients, there were clear outbreaks of cases in 2003, 2006-2007, and  
5  
6 2011, with a few cases occurring in the inter-epidemic periods. There were relatively steady  
7  
8 numbers of RWE cases every year during the study period. There were no corresponding  
9  
10 increased cases in MP pneumonia epidemic years except in 2007 (Fig. 2). No MP pneumonia  
11  
12 patient who was re-admitted due to MP reinfection across the epidemics was observed during  
13  
14 study period. The mean age and age distribution were similar, and the peak age groups were  
15  
16 2-5 years of age in both groups (Fig. 3). In seasonality of both groups, MP pneumonia was  
17  
18 prevalent in decreasing order of autumn, summer, winter, and spring, while patients with  
19  
20 RWE were most prevalent in autumn, followed by spring, winter, and summer (Fig. 4).  
21  
22  
23  
24

### 25 **Demographic and clinical characteristics of MP pneumonia and RWE groups**

26  
27 Demographic, clinical and laboratory data in both groups are shown in Table 1. The mean  
28  
29 age and age distribution were similar in both groups as shown in Fig. 2 (5.4 years vs. 5.6  
30  
31 years,  $P = 0.312$ ). Both groups had male predominance, and there were more males in the  
32  
33 RWE group. As expected, cases with wheezing at presentation, the proportion of patients  
34  
35 with past history or family history of allergic diseases, and past history of wheezing were  
36  
37 higher in the RWE group. Recurrent wheezing after discharge was observed in 38 of 180  
38  
39 patients with MP pneumonia and 141 of the 206 patients with RWE ( $P < 0.001$ ).  
40  
41  
42

43  
44 In MP pneumonia patients, 52 of the total 501 patients (10.4%) had wheezing at  
45  
46 presentation, 72 (14.4%) had a past history of allergic diseases, 15 (3%) had RWE according  
47  
48 to our definition, and 40 (8%) had a family history of allergic diseases. When we divided the  
49  
50 MP pneumonia patients into two groups of patients with wheezing ( $n=52$ ) and without  
51  
52 wheezing ( $n=449$ ), the patients with wheezing were younger (3.7 years vs. 5.6 years,  $P <$   
53  
54 0.001) and had higher proportions of past history allergic diseases and wheezing history and  
55  
56 higher values of leukocyte count and eosinophil differential (Table 2). Among the 52 MP  
57  
58 pneumonia patients with wheezing at admission, 10 were patient with RWE, while 42 had no  
59  
60

1  
2  
3  
4 previous RWE history. Thus, in this study, 66% (10 of 15) of patients with RWE history  
5  
6 presented with wheezing, while 8.6% of patients without RWE history (42 of 486) had  
7  
8 wheezing at presentation. In a follow-up study of patients who visited two or more times after  
9  
10 discharge, 13 (including 5 cases of RWE) of 21 MP pneumonia patients with initial wheezing  
11  
12 and 25 (including 2 cases of RWE) of 159 MP pneumonia patients without wheezing had at  
13  
14 least one wheezing episode after discharge (Table 2). Although not all patients were  
15  
16 followed-up, it was estimated that at least 31 of the total MP pneumonia patients (n=501,  
17  
18 6.2%) showed a recurrent wheezing after initial MP infection.  
19  
20  
21  
22  
23  
24

## 25 **DISCUSSION**

26  
27  
28 In this study, we found that patients with MP pneumonia and patients with RWE had a  
29  
30 similar mean age and age distribution during the past decade. However, the annual number of  
31  
32 cases in the two groups was quite different; there were relatively stable number of annual  
33  
34 cases in patients with RWE, without a corresponding increase in cases during or after MP  
35  
36 pneumonia epidemic years. Although reinfection with MP reported to be not uncommon in  
37  
38 other studies based on polymerase chain reaction (PCR) or single serologic test-based  
39  
40 studies,<sup>16</sup> we found that there were no serologically confirmed reinfected MP pneumonia  
41  
42 patients among 793 patients during study period, except a few readmitted patients with  
43  
44 complications of initial MP infection in each epidemic. It suggests that reattack of MP  
45  
46 pneumonia in children is extremely rare, and once infected children seem to have immunity  
47  
48 to other MP strains in future epidemics including macrolide-resistant MP strains.<sup>14</sup> During a  
49  
50 MP epidemic, the majority of susceptible children are asymptomatic or have mild symptoms  
51  
52 such as fever and sore throat, and only a small part of MP infected patients may affect  
53  
54 pneumonia.<sup>1,2</sup> Moreover, since MP reinfection is also rare in asthmatics of all age, our  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 epidemiological data might not be associated with the situations where asthmatics have  
5 reasons for increase of admission such as exacerbation or initiation of RWE or asthma.  
6  
7

8  
9 MP pneumonia patients in this study showed a similar prevalence of allergic diseases  
10 compared to data from previous nationwide questionnaire-based studies in Korea: 3%  
11 (15/501) and 14.4% (72/501) of MP pneumonia patients had a past history of RWE (asthma)  
12 and a past history of allergic diseases, respectively. Whereas 5.8% of 6- to 7-year-old school  
13 children had asthma history in 2000, and 13.5% of children reported a diagnosis of atopic  
14 dermatitis in 2008-2011 in Korea.<sup>17,18</sup> In this study, among 52 MP pneumonia patients with  
15 initial wheezing, 10 were patients with RWE, while 42 had no previous wheezing history.  
16 Therefore, 66.6% (10 of 15) of patients with RWE, and 8.6% (42 of 486) of patients without  
17 RWE history were wheezing, and it suggests that patients with RWE or asthma with first-  
18 time MP infection might be prone to a wheezing episode as well as other respiratory virus  
19 infections as compounding factors of asthma exacerbation. Also, we found that after MP  
20 infection, at least 6% of MP pneumonia patients showed subsequent wheezing during at least  
21 over 3 years after initial MP infection. A large proportion of patients who experienced lower  
22 respiratory infections caused by RSV and rhinoviruses were reported to show recurrent  
23 wheezing after initial infection, especially when they were infected with other respiratory  
24 agents.<sup>19,20</sup> A study reported that approximately 50% of children affected with severe RSV  
25 bronchiolitis had a subsequent asthma diagnosis.<sup>19</sup> In Korea, since the majority of children  
26 might affect RSV during infancy and early childhood period as well as in other populations, it  
27 is possible that majority of MP infected patients experience RSV infection prior to MP  
28 infection. On the other hand, other authors reported that some patients with severe MP  
29 pneumonia had prolonged anatomical abnormalities, suggestive of small airway  
30 obstruction,<sup>21</sup> and some patients had reduced pulmonary function after MP infection.<sup>8</sup> Thus,  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 patients with severe lung injury caused by any respiratory pathogens may be prone to  
5  
6 recurrent wheezing and subsequent diagnosis of asthma.  
7

8  
9 We found that WBC count, eosinophil differential, IgG, and IgE values were higher in the  
10  
11 RWE group than those in the MP pneumonia group which had similar mean age. It could in  
12  
13 part be explained that different activation of immune system of the host against the insults  
14  
15 from RWE which induces chronic or repeated inflammation may be reflected in these  
16  
17 laboratory findings.  
18

19  
20 Previous studies have reported that asthma patients are more likely to be infected or  
21  
22 colonized with MP compared to healthy controls, and MP infection in chronic asthmatics  
23  
24 might be associated with persistent bronchial hyperresponsiveness and exacerbation.<sup>10-13</sup> MP  
25  
26 pneumonia epidemics are cyclic in 3-4-year intervals, and the duration of an epidemic is  
27  
28 generally limited to 1 year or occasionally 2 years, and during the inter-epidemic period of  
29  
30 the 2-3 years there are a few patients as observed in this study.<sup>14</sup> There are many  
31  
32 asymptomatic healthy MP carriers during the epidemic periods, especially young children,  
33  
34 who may serve as reservoirs for the spread of MP infection.<sup>22-24</sup> It is natural that colonization  
35  
36 of MP during MP pneumonia epidemics can occur in asthma patients and old persons as well  
37  
38 as in healthy young children and adults since colonization does not mean the 'infection'. The  
39  
40 prevalent rates of MP colonization between the asthma group and the control groups could be  
41  
42 influenced by the MP epidemic year during the study period. Thus, patient selection bias  
43  
44 could be considered if a study period is long and different in both groups. Wood et al.  
45  
46 reported that the rates of MP colonization in asthmatics and healthy children during the same  
47  
48 study period were similar using a sensitive PCR method,<sup>13</sup> suggesting that colonization occurs  
49  
50 equally in the two groups. One study reported that the status of asthma control and the lung  
51  
52 function tests were not different between asthmatic patients with chronic MP infection and  
53  
54 those without, indicating the similar severity of asthma between the group.<sup>25</sup>  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 In this study, the numbers of patient with RWE during a recent decade did not change with  
5  
6 a rather decreasing trend in recent years. Moreover, we have experienced that asthma severity  
7  
8 might change to a milder phenotype in Korea over time. A recent population-based study in  
9  
10 Korea also indicated that the prevalence of asthma was reduced in recent years.<sup>26</sup> Changing  
11  
12 epidemiology in infectious disease and infection-related immune-mediated diseases,  
13  
14 including scarlet fever, pandemic influenza, acute rheumatic fever, acute post-streptococcal  
15  
16 glomerulonephritis, and Kawasaki disease, has been well documented in Korea; initially  
17  
18 severe disease phenotypes have changed to milder phenotypes over time.<sup>27-30</sup> Because allergic  
19  
20 diseases, including asthma, may be associated with various pathogen infections and  
21  
22 environmental factors,<sup>31,32</sup> it is possible that the changing epidemiology of childhood asthma  
23  
24 occurs over time in the populations.  
25  
26  
27  
28

29  
30 There are some limitations to this retrospective study. We evaluated only admitted patient  
31  
32 groups with a part of the follow-up subjects at a single hospital. History of allergic diseases  
33  
34 was not as precise as in International Study of Asthma and Allergies in Childhood (ISAAC)  
35  
36 studies. In our definition of RWE in the present study, the pneumonia patients with first  
37  
38 wheezing, regardless of severity of respiratory symptoms, were not included in the asthma  
39  
40 group. Considering the age distribution of patients, larger part of patients might be the  
41  
42 transient recurrent wheezers and small part of true asthma patients who experience and  
43  
44 progress recurrent wheezing into adulthood might be included in the RWE group. Further  
45  
46 multicenter studies with prospective designs are needed for exact epidemiological  
47  
48 relationship between MP infection and childhood asthma.  
49  
50  
51

52  
53 In conclusions, a small part of MP pneumonia patients had a subsequent wheezing after  
54  
55 initial MP infection as well as those observed in other respiratory pathogen infections.  
56  
57 Patients with RWE have a greater likelihood of experiencing wheezing than non-asthmatics  
58  
59 when they had an initial MP infection, suggesting that MP infection is one of exacerbation  
60

1  
2  
3  
4 factors in childhood asthma. However, we found no corresponding increase in the number of  
5  
6 patients with RWE in MP pneumonia epidemic periods, and this finding may in part be  
7  
8 explained that MP reinfection are very rare in children including patients with RWE or  
9  
10 asthma as shown in this study.  
11  
12  
13  
14

### 15 16 **Acknowledgements**

17  
18 The authors thank Drs. Eun-Kyung Kim, Sung-Churl Lee and other colleagues for help in  
19  
20 data collection during study period.  
21  
22  
23  
24

### 25 26 **Contributors**

27  
28 KYL designed and conceptualized and the study, and drafted the manuscript. JUR  
29  
30 participated in preliminary data collection, and wrote the initial manuscript. HMK and EAY  
31  
32 analyzed data and revised the manuscript for critical content. All authors approved the final  
33  
34 manuscript as submitted and agree to be accountable for all aspects of the work.  
35  
36

### 37 38 **Funding statement**

39  
40 This research received no specific grant from any funding agency in the public, commercial  
41  
42 or not-for-profit sectors.  
43  
44

### 45 46 **Competing interests**

47  
48 None declared.  
49

### 50 51 **Ethic approval**

52  
53 The study was approved by the Institutional Review Board of The Catholic University of  
54  
55 Korea Daejeon St. Mary's Hospital (DC17RESI0053).  
56

### 57 58 **Data sharing statement**

59  
60 Data of the study are available from the corresponding author (KYL).



## REFERENCES

1. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of *Mycoplasma pneumoniae* infections. *FEMS Microbiol Rev* 2008;32:956-73.
2. Lee KY. Pediatric respiratory infections by *Mycoplasma pneumoniae*. *Expert Rev Anti Infect Ther* 2008;6:509-21.
3. Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from an epidemiological approach. *Paediatr Respir Rev* 2004;5:155-61.
4. Strina A, Barreto ML, Cooper PJ, *et al*. Risk factors for non-atopic asthma/wheeze in children and adolescents: a systematic review. *Emerg Themes Epidemiol* 2014;11:5.
5. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998;351:1225-32.
6. Asher MI, Montefort S, Björkstén B, *et al*; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 2006;368:733-43.
7. Johnston SL, Pattemore PK, Sanderson G, *et al*. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995;310:1225-9.
8. Biscardi S, Lorrot M, Marc E, *et al*. *Mycoplasma pneumoniae* and asthma in children. *Clin Infect Dis* 2004;38:1341-6.
9. Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of asthma. *Expert Rev Respir Med* 2010;4:71-83.
10. Kraft M, Cassell GH, Henson JE, *et al*. Detection of *Mycoplasma pneumoniae* in the airways of adults with chronic asthma. *Am J Respir Crit Care Med* 1998;158:998-1001.

11. Sutherland ER, King TS, Icitovic N, *et al*; National Heart, Lung and Blood Institute's Asthma Clinical Research Network. A trial of clarithromycin for the treatment of suboptimally controlled asthma. *J Allergy Clin Immunol* 2010;126:747-53.
12. Varshney AK, Chaudhry R, Saharan S, *et al*. Association of *Mycoplasma pneumoniae* and asthma among Indian children. *FEMS Immunol Med Microbiol* 2009;56:25-31.
13. Wood PR, Hill VL, Burks ML, *et al*. *Mycoplasma pneumoniae* in children with acute and refractory asthma. *Ann Allergy Asthma Immunol* 2013;110:328-34.
14. Kim EK, Youn YS, Rhim JW, *et al*. Epidemiological comparison of three *Mycoplasma pneumoniae* pneumonia epidemics in a single hospital over 10 years. *Korean J Pediatr* 2015;58:172-7.
15. Lee SC, Youn YS, Rhim JW, *et al*. Early serologic diagnosis of *Mycoplasma pneumoniae* pneumonia: an observational study on changes in titers of specific-IgM antibodies and cold agglutinins. *Medicine* 2016;95:e3605.
16. Papaetis GS, Anastasakou E, Tselou T, *et al*. Serological evidence of *Mycoplasma pneumoniae* infection in patients with acute exacerbation of COPD: analysis of 100 hospitalizations. *Adv Med Sci* 2010;55:235-241.
17. Lee SI. Prevalence of childhood asthma in Korea: international study of asthma and allergies in childhood. *Allergy Asthma Immunol Res* 2010;2:61-4.
18. Lee JH, Han KD, Kim KM, *et al*. Prevalence of atopic dermatitis in Korean children based on data from the 2008-2011 Korean National Health and Nutrition Examination Survey. *Allergy Asthma Immunol Res* 2016;8:79-83.
19. Bacharier LB, Cohen R, Schweiger T, *et al*. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. *J Allergy Clin Immunol* 2012;130:91-100.

- 1  
2  
3  
4 20. Jackson DJ, Gangnon RE, Evans MD, *et al.* Wheezing rhinovirus illnesses in early life  
5 predict asthma development in high-risk children. *Am J Respir Crit Care Med*  
6  
7 2008;178:667-72.  
8  
9  
10  
11 21. Kim CK, Chung CY, Kim JS, Kim *et al.* Late abnormal findings on high-resolution  
12 computed tomography after *Mycoplasma pneumoniae*. *Pediatrics* 2000;105:372-378.  
13  
14  
15 22. Gnarp J, Lundback A, Sundelof B, *et al.* Prevalence of *Mycoplasma pneumoniae* in  
16 subjectively healthy individuals. *Scand J Infect Dis* 1992;24:161-4.  
17  
18  
19 23. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, *et al.* Results of molecular detection of  
20 *Mycoplasma pneumoniae* among patients with acute respiratory infection and in their  
21 household contacts reveals children as human reservoirs. *J Infect Dis* 2001;183:675-8.  
22  
23  
24 24. Spuesens EB, Fraaij PL, Visser EG, *et al.* Carriage of *Mycoplasma pneumoniae*  
25 in the upper respiratory tract of symptomatic and asymptomatic children: an  
26 observational study. *PLoS Med* 2013;10:e1001444.  
27  
28  
29 25. Ansarin K, Abedi S, Ghotaslou R, *et al.* Infection with *Mycoplasma pneumoniae* is not  
30 related to asthma control, asthma severity, and location of airway obstruction. *Int J Gen*  
31 *Med* 2010;4:1-4.  
32  
33  
34 26. Kim BK, Kim JY, Kang MK, *et al.* Allergies are still on the rise? A 6-year nationwide  
35 population-based study in Korea. *Allergol Int* 2016;65:186-91.  
36  
37  
38 27. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever,  
39 streptococcal disease, and scarlet fever: the decline of rheumatic fever. *Rev Infect Dis*  
40 1989;11:928-53.  
41  
42  
43 28. Rhim JW, Go EJ, Lee KY, *et al.* Pandemic2009 H1N1 virus infection in children and  
44 adults: A cohort study at a single hospital throughout the epidemic. *Int Arch Med*  
45 2012;5:13.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 29. Keum SW, Hur SM, Youn YS, *et al.* Changes in acute poststreptococcal  
5  
6 glomerulonephritis: an observation study at a single Korean hospital over two decades.  
7  
8 *Child Kidney Dis* 2015;19:112-7.  
9  
10  
11 30. Kil HR, Yu JW, Lee SC, *et al.* Changes in clinical and laboratory features of Kawasaki  
12  
13 disease noted over time in Daejeon, Korea. *Pediatr Rheumatol* 2017;15:60.  
14  
15  
16 31. Atkinson TP. Is asthma an infectious disease? New evidence. *Curr Allergy Asthma Rep*  
17  
18 2013;13:702-9.  
19  
20  
21 32. Hossaini RF, Ghaffari J, Ranjbar A, *et al.* Infections in children with asthma. *J Pediatr*  
22  
23 *Rev* 2013;1:25-36.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Clinical and laboratory findings of the patients with MP pneumonia or recurrent wheezing episode (RWE)**

	MP pneumonia (n = 501)	RWE (n = 384)	<i>P</i>
Clinical characteristics			
Age (y)	5.4 ± 3.4	5.6 ± 3.5	0.31
Male : female	255/246	256/128	<.001
Wheeze at presentation, n (%)	52 (10.4)	384 (100)	<.001
Past history of allergy*, n (%)	72 (14.4)	379 (98.7)	<.001
Past history of wheeze, n (%)	15 (3.0)	384 (100)	<.001
Family history of allergy, n (%)	40 (8.0)	134 (34.9)	<.001
Wheeze after discharge, n (%)	38/180 (21.1)	141/206 (68.4)	<.001
Laboratory findings			
Leukocyte (/μL)	8800 ± 4500	11100 ± 4200	<.001
Eosinophil (%)	2.2 ± 2.9	3.8 ± 3.9	<.001
IgG (mg/dL)	899 ± 235	946 ± 232	<.001
IgE (IU/mL)	267 ± 391	617 ± 673	<.001

\* Number of patients who had history to be diagnosed as having asthma, allergic rhinitis, and/or atopic dermatitis

**Table 2. Clinical and laboratory findings of MP pneumonia patients with wheezing and without wheezing**

	Wheezing (n = 52)	No Wheezing (n = 449)	<i>P</i>
Clinical characteristics			
Age (y)	3.7 ± 3.0	5.6 ± 3.4	<.001
Male : female	32/20	223/226	0.11
Past history of allergy*, n (%)	16 (30.8)	56 (12.5)	0.01
Past history of wheeze, n (%)	10 (19.2)	5 (1.1)	<.001
Family history of allergy, n (%)	8 (15.4)	32 (7.1)	0.05
Wheeze after discharge, n (%)	13/21 (61.9)	25/159 (15.7)	<.001
Laboratory findings			
Leukocyte (x10 <sup>3</sup> //μL)	10400 ± 5400	8700 ± 4.3	0.03
Eosinophil (%)	3.0 ± 3.2	2.1 ± 2.9	0.08
IgG	873 ± 219	903 ± 238	0.43
IgE	407 ± 609	249 ± 350	0.11

\* Number of patients who had history to be diagnosed as having asthma, allergic rhinitis, and/or atopic dermatitis

**Figure legends**

Figure 1. Flow diagram of the patient selection in this study

Figure 2. Annual cases of MP pneumonia and recurrent wheezing episode during 2003-2014

Figure 3. Age distribution in MP pneumonia and recurrent wheezing episode groups

Figure 4. Seasonality in MP pneumonia and recurrent wheezing episode groups

For peer review only




Figure 1. Flow diagram of the patient selection in this study

254x190mm (96 x 96 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 2. Annual cases of MP pneumonia and recurrent wheezing episode during 2003-2014  
254x190mm (96 x 96 DPI)




Fig. 3. Age distribution in MP pneumonia and recurrent wheezing episode groups

254x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 4. Seasonality in MP pneumonia and recurrent wheezing episode groups  
254x190mm (96 x 96 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4
Objectives	3	State specific objectives, including any pre-specified hypotheses	P4-5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	P5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	P5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P5
Bias	9	Describe any efforts to address potential sources of bias	P5
Study size	10	Explain how the study size was arrived at	P5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P6
		(b) Describe any methods used to examine subgroups and interactions	P6
		(c) Explain how missing data were addressed	-
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	-

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P6
		(b) Give reasons for non-participation at each stage	P6
		(c) Consider use of a flow diagram	P6 (figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P6
		(b) Indicate number of participants with missing data for each variable of interest	P8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	P8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	-
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	P6-8-
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	-
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P6-8
		(b) Report category boundaries when continuous variables were categorized	P6-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	P8-9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	P8-11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Epidemiological relationship between *Mycoplasma pneumoniae* pneumonia and recurrent wheezing episode in children: an observational study at a single hospital in Korea

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026461.R2
Article Type:	Research
Date Submitted by the Author:	07-Feb-2019
Complete List of Authors:	Rhim, Jung-Woo; The Catholic University of Korea Daejeon St. Mary's Hospital Kang, Hyun-Mi; The Catholic University of Korea, Daejeon St. Mary's Hospital, Department of Pediatrics Yang, Eun-Ae; The Catholic University of Korea Daejeon St. Mary's Hospital Lee, Kyung-Yil; The Catholic University of Korea, Daejeon St Mary's Hospital, Department of Pediatrics
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Immunology (including allergy), Paediatrics
Keywords:	<i>Mycoplasma pneumoniae</i> pneumonia, Recurrent wheezing episode, Asthma < THORACIC MEDICINE, Epidemiology < INFECTIOUS DISEASES, children

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5 **Epidemiological relationship between *Mycoplasma pneumoniae* pneumonia**  
6  
7  
8 **and recurrent wheezing episode in children: an observational study at a**  
9  
10  
11 **single hospital in Korea**  
12  
13  
14  
15

16 Jung-Woo Rhim, Hyun-Mi Kang, Eun-Ae Yang, Kyung-Yil Lee

17  
18 Department of Pediatrics, Daejeon St. Mary's Hospital, College of Medicine, The Catholic  
19 University of Korea, Seoul, Republic of Korea.  
20  
21  
22

23  
24  
25 **Affiliations:**

26  
27 Department of Pediatrics, The Catholic University of Korea Daejeon St. Mary's Hospital,  
28 Daejeon, Republic of Korea  
29  
30  
31

32  
33  
34 **Corresponding Author:**

35  
36 Kyung-Yil Lee, MD

37  
38 Department of Pediatrics, The Catholic University of Korea Daejeon St. Mary's Hospital, 64  
39 Daeheung-ro, Jung-gu, Daejeon 34943, Republic of Korea  
40  
41

42  
43 Tel. +82-42-220-9540, Fax. +82-42-221-2925,  
44

45  
46 E-mail: leekyungyil@catholic.ac.kr  
47  
48  
49

50  
51 **Word count: 2,603** (except abstract and references)  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** This study was aimed to evaluate epidemiological and clinical relationship between MP infection and childhood recurrent wheezing episode (RWE).

**Design:** Retrospective case note review.

**Setting:** Paediatric department at a single Korean institution.

**Participants:** Consecutive admitted patients with MP pneumonia and RWE (0-15 years of age) between 2003 and 2014.

**Methods:** The retrospective medical records of patients with MP pneumonia (n=793 for epidemiological analysis and n=501 for clinical analysis) and those with RWE (n=384) from 2003 to 2014 were analyzed. Diagnosis of MP pneumonia was made based on 2-times titration of IgM antibody during hospitalization. An RWE patient was defined as one with expiratory wheezing with at least one or more wheezing episodes based on medical records.

**Results:** During 3 MP pneumonia epidemics, there were no corresponding increases of patients with RWE in the epidemic years. In the 501 MP pneumonia patients, 52 (10.4%) had wheezing at presentation and 15 (3%) had RWE. The MP pneumonia patients with wheezing at presentation (n=52) were younger and were more likely to have an allergic disease history than those without wheezing (n=449). Among wheezing patients at presentation, 10 patients had previously RWE history. In a follow-up study, 13 patients (including 5 RWE) with initial wheezing and 25 patients (including 2 RWE) without wheezing had wheezy episodes after discharge. Among the total 501 patients, it was estimated that at least 31 MP pneumonia patients (6.2%) showed recurrent wheezing after initial MP infection.

**Conclusions:** A small part of children with MP pneumonia showed recurrent wheezing after MP pneumonia, and patients with RWE had a greater likelihood of experiencing wheezing when they had an initial MP infection. However, there were no increased admitted patients with RWE in MP pneumonia epidemic periods because of rarity of MP reinfection in children including patients with RWE or asthma.



1  
2  
3  
4 **Key words:** asthma, children, epidemiology, *Mycoplasma pneumoniae* pneumonia, recurrent  
5  
6 wheezing  
7  
8  
9

10  
11 **Strengths and limitations of this study**  
12

- 13 - This may be the first long-term epidemiological study regarding relationship between  
14  
15 *Mycoplasma pneumoniae* (MP) infection and recurrent wheezing episode (RWE).  
16  
17 - Two-times examination of anti-MP IgM for diagnosis of MP pneumonia strengthened  
18  
19 accuracy for patient selection.  
20  
21  
22 - We discussed unsolved issues regarding MP infection and childhood asthma.  
23  
24 - There were limitations in this study in regards to the following: retrospective analysis, data  
25  
26 collected from a single centre, and patient selection under our definition of RWE (or  
27  
28 childhood asthma).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

*Mycoplasma pneumoniae* (MP) is one of the major pathogens in respiratory tract infections in children and young adults, manifesting from asymptomatic infection to potential fatal pneumonia. MP pneumonia is an endemic disease in large communities, but it occurs in nationwide cyclic epidemics of 3-7 year intervals. Also, MP is associated with a wide spectrum of other organ-specific diseases including neurologic, dermatologic, hepatic, cardiac, musculoskeletal, hematologic diseases and possibly bronchial asthma.<sup>1,2</sup>

Childhood asthma is a complex disease process that can be classified into heterogeneous clinical phenotypes.<sup>3</sup> The diverse phenotypes of childhood asthma may be associated with host factors, including the developing immune and respiratory systems and individual genetic variations. Childhood asthma is also influenced by environmental factors such as socio-economic and/or cultural differences across populations.<sup>3,4</sup> Therefore, diagnosis of asthma in children, especially in children under 5 years of age, could not be defined definitely, and the phenotypes of childhood asthma, such as the prevalence of asthma and frequency of severe asthma, could differ among populations.<sup>5,6</sup> It has been suggested that initiation of asthma and acute exacerbation of asthma are associated with a variety of respiratory pathogens, including respiratory syncytial viruses (RSV), rhinoviruses and MP, although the exact reasons are still not fully understood.<sup>7-9</sup> In addition, it has been suggested that chronic MP infection is related to persistent bronchial hyper-responsiveness, chronic inflammation, and acute exacerbation in children and adults with asthma.<sup>10-13</sup>

In Korea, MP pneumonia epidemics have been observed every 3 to 4 years from the mid-1980s to present. We recently found that during 2003-2012, there were three nationwide MP pneumonia epidemics, all of which had similar epidemiological patterns including age distribution and seasonal pattern.<sup>14</sup> In this study, we evaluated the epidemiological and clinical characteristics of patients with MP pneumonia and those with recurrent wheezing

1  
2  
3  
4 episode (RWE) admitted during the 2003-2014 period, and we compared the data in both  
5  
6 diseases. Also, we discussed the relationship between MP infection and childhood asthma.  
7  
8  
9

## 10 11 **METHODS**

### 12 13 **Study design and setting**

14  
15 This study was a retrospective study conducted at Department of Paediatrics, The Catholic  
16  
17 University of Korea Daejeon St. Mary's Hospital, a secondary referral hospital performing  
18  
19 primary care for patients with MP pneumonia or RWE.  
20  
21  
22

### 23 24 **Patients and public involvement**

25  
26 Patients and public were not involved in the study due to its retrospective nature.  
27

### 28 29 **Patients and data collection**

30  
31 We performed a retrospective analysis of medical records of patients with MP pneumonia or  
32  
33 RWE who were admitted to our institution from January 2003 to December 2014. In this  
34  
35 study, diagnosis of MP pneumonia was based on chest radiographic findings and 2-times  
36  
37 titration of IgM antibody (Serodia-Myco II, Fujirebio Inc., Tokyo, Japan; positive cutoff  
38  
39 value  $\geq 1:40$ ) at presentation and before discharge. Briefly, diagnoses of MP pneumonia were  
40  
41 made when patients showed seroconversion (negative to positive), 4-fold or greater increase in IgM  
42  
43 titres, or high titres of  $> 1:640$  in initial and follow up examinations during the disease course.  
44  
45 Patients who received the test once or those who did not increase or decreased titres were excluded  
46  
47 when initial titres were  $< 1:320$ .<sup>14,15</sup>  
48  
49

50  
51 The subjects with RWE were collected through the diagnostic code number J459 (asthma,  
52  
53 asthma nature, bronchial asthma, and infantile asthma). However, we used the term RWE in  
54  
55 this study, because majority of patients were under 5 years of age and some patients over 6  
56  
57 years of age did not perform confirmative study for asthma such as pulmonary function test.  
58  
59  
60

1  
2  
3  
4 An RWE patient was defined as one with expiratory wheezing at admission with at least one  
5  
6 or more wheezing episodes within 6 months before admission, regardless of patient's age  
7  
8 based on the medical records. Patients with first wheezing at admission for any respiratory  
9  
10 tract infection, including MP pneumonia, were excluded from the RWE group. Readmitted  
11  
12 patients with RWE in the same year or different year were included in this series (35  
13  
14 episodes). Clinical and laboratory parameters were evaluated and compared between the  
15  
16 groups. After discharge, wheezing episodes were evaluated through the medical records in  
17  
18 both patient groups who revisited the outpatient clinic or had readmission at least two or  
19  
20 more times from the date of discharge to December 2014.  
21  
22  
23

### 24 25 **Statistical analysis**

26  
27 All calculations were performed with SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA).  
28  
29 Comparisons between groups were performed using the Student's t-test, chi-square test, and  
30  
31 Fisher's exact test, and the data were expressed as mean  $\pm$  standard deviation (SD) for  
32  
33 continuous variables. A *P* value of  $<0.05$  was considered statistically significant.  
34  
35  
36  
37  
38

## 39 **RESULTS**

40  
41 The subjects in the present study were 793 patients with MP pneumonia and 384 patients  
42  
43 with RWE during the study period. For epidemiological comparison, a total 793 patients were  
44  
45 used, as shown in previously published article.<sup>14</sup> For clinical comparison between the groups,  
46  
47 a total of 501 MP pneumonia patients that were admitted during the recent epidemics (241  
48  
49 cases in 2007-2006, and 260 cases in 2011), and 384 patients with RWE were analyzed (Fig.  
50  
51 1). During the study period, the total number of admitted patients at our department was a  
52  
53 total 25,911 (except nursery patients). There were approximately 2,100 admitted patients per  
54  
55 year with some variations in each year.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9 Most of MP pneumonia patients had follow-up period at least 3 years from last epidemic year  
10 of 2011, but the follow-up subjects satisfied with our selection criteria were 180 among 501  
11 cases in the MP pneumonia group and 206 among 384 cases in the RWE group.  
12  
13  
14

### 15 **Epidemiological data of MP pneumonia and RWE from 2003 to 2014**

16  
17  
18 In MP pneumonia patients, there were clear outbreaks of cases in 2003, 2006-2007, and  
19 2011, with a few cases occurring in the inter-epidemic periods. There were relatively steady  
20 numbers of RWE cases every year during the study period. There were no corresponding  
21 increased cases in MP pneumonia epidemic years except in 2007 (Fig. 2). No MP pneumonia  
22 patient who was re-admitted due to MP reinfection across the epidemics was observed during  
23 study period. The mean age and age distribution were similar, and the peak age groups were  
24 2-5 years of age in both groups (Fig. 3). In seasonality of both groups, MP pneumonia was  
25 prevalent in decreasing order of autumn, summer, winter, and spring, while patients with  
26 RWE were most prevalent in autumn, followed by spring, winter, and summer (data not  
27 shown).  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Demographic and clinical characteristics of MP pneumonia and RWE groups**

42  
43 Demographic, clinical and laboratory data in both groups are shown in Table 1. The mean  
44 age and age distribution were similar in both groups as shown in Fig. 3 (5.4 years vs. 5.6  
45 years,  $P = 0.312$ ). Both groups had male predominance, and there were more males in the  
46 RWE group. As expected, cases with wheezing at presentation, the proportion of patients  
47 with past history or family history of allergic diseases, and past history of wheezing were  
48 higher in the RWE group. Recurrent wheezing after discharge was observed in 38 of 180  
49 patients with MP pneumonia and 141 of the 206 patients with RWE ( $P < 0.001$ ).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 In MP pneumonia patients, 52 of the total 501 patients (10.4%) had wheezing at  
5  
6 presentation, 72 (14.4%) had a past history of allergic diseases, 15 (3%) had RWE according  
7  
8 to our definition, and 40 (8%) had a family history of allergic diseases. When we divided the  
9  
10 MP pneumonia patients into two groups of patients with wheezing (n=52) and without  
11  
12 wheezing (n=449), the patients with wheezing were younger (3.7 years vs. 5.6 years,  $P <$   
13  
14 0.001) and had higher proportions of past history allergic diseases and wheezing history and  
15  
16 higher values of leukocyte count and eosinophil differential (Table 2). Among the 52 MP  
17  
18 pneumonia patients with wheezing at admission, 10 were patient with RWE, while 42 had no  
19  
20 previous RWE history. Thus, in this study, 66% (10 of 15) of patients with RWE history  
21  
22 presented with wheezing, while 8.6% of patients without RWE history (42 of 486) had  
23  
24 wheezing at presentation. In a follow-up study of patients who visited two or more times after  
25  
26 discharge, 13 (including 5 cases of RWE) of 21 MP pneumonia patients with initial wheezing  
27  
28 and 25 (including 2 cases of RWE) of 159 MP pneumonia patients without wheezing had at  
29  
30 least one wheezing episode after discharge (Table 2). Although not all patients were  
31  
32 followed-up, it was estimated that at least 31 of the total MP pneumonia patients (n=501,  
33  
34 6.2%) showed a recurrent wheezing after initial MP infection.  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **DISCUSSION**

45  
46 In this study, we found that patients with MP pneumonia and patients with RWE had a  
47  
48 similar mean age and age distribution during the past decade. However, the annual number of  
49  
50 cases in the two groups was quite different; there were relatively stable number of annual  
51  
52 cases in patients with RWE, without a corresponding increase in cases during or after MP  
53  
54 pneumonia epidemic years. Although reinfection with MP reported to be not uncommon in  
55  
56 other studies based on polymerase chain reaction (PCR) or single serologic test-based  
57  
58  
59  
60

1  
2  
3  
4 studies,<sup>16</sup> we found that there were no serologically confirmed reinfected MP pneumonia  
5 patients among 793 patients during study period, except a few readmitted patients with  
6 complications of initial MP infection in each epidemic. It suggests that reattack of MP  
7 pneumonia in children is extremely rare, and once infected children seem to have immunity  
8 to other MP strains in future epidemics including macrolide-resistant MP strains.<sup>14</sup> During a  
9 MP epidemic, the majority of susceptible children are asymptomatic or have mild symptoms  
10 such as fever and sore throat, and only a small part of MP infected patients may affect  
11 pneumonia.<sup>1,2</sup> Moreover, since MP reinfection is also rare in asthmatics of all age, our  
12 epidemiological data might not be associated with the situations where asthmatics have  
13 reasons for increase of admission such as exacerbation or initiation of RWE or asthma.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 MP pneumonia patients in this study showed a similar prevalence of allergic diseases  
28 compared to data from previous nationwide questionnaire-based studies in Korea: 3%  
29 (15/501) and 14.4% (72/501) of MP pneumonia patients had a past history of RWE (asthma)  
30 and a past history of allergic diseases, respectively. Whereas 5.8% of 6- to 7-year-old school  
31 children had asthma history in 2000, and 13.5% of children reported a diagnosis of atopic  
32 dermatitis in 2008-2011 in Korea.<sup>17,18</sup> In this study, among 52 MP pneumonia patients with  
33 initial wheezing, 10 were patients with RWE, while 42 had no previous wheezing history.  
34 Therefore, 66.6% (10 of 15) of patients with RWE, and 8.6% (42 of 486) of patients without  
35 RWE history were wheezing, and it suggests that patients with RWE or asthma with first-  
36 time MP infection might be prone to a wheezing episode as well as other respiratory virus  
37 infections as compounding factors of asthma exacerbation. Also, we found that after MP  
38 infection, at least 6% of MP pneumonia patients showed subsequent wheezing during at least  
39 over 3 years after initial MP infection. A large proportion of patients who experienced lower  
40 respiratory infections caused by RSV and rhinoviruses were reported to show recurrent  
41 wheezing after initial infection, especially when they were infected with other respiratory  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 agents.<sup>19,20</sup> A study reported that approximately 50% of children affected with severe RSV  
5  
6 bronchiolitis had a subsequent asthma diagnosis.<sup>19</sup> In Korea, since the majority of children  
7  
8 might affect RSV during infancy and early childhood period as well as in other populations, it  
9  
10 is possible that majority of MP infected patients experience RSV infection prior to MP  
11  
12 infection. On the other hand, other authors reported that some patients with severe MP  
13  
14 pneumonia had prolonged anatomical abnormalities, suggestive of small airway  
15  
16 obstruction,<sup>21</sup> and some patients had reduced pulmonary function after MP infection.<sup>8</sup> Thus,  
17  
18 patients with severe lung injury caused by any respiratory pathogens may be prone to  
19  
20 recurrent wheezing and subsequent diagnosis of asthma.  
21  
22  
23

24  
25 We found that WBC count, eosinophil differential, IgG, and IgE values were higher in the  
26  
27 RWE group than those in the MP pneumonia group which had similar mean age. It could in  
28  
29 part be explained that different activation of immune system of the host against the insults  
30  
31 from RWE which induces chronic or repeated inflammation may be reflected in these  
32  
33 laboratory findings.  
34  
35

36  
37 Previous studies have reported that asthma patients are more likely to be infected or  
38  
39 colonized with MP compared to healthy controls, and MP infection in chronic asthmatics  
40  
41 might be associated with persistent bronchial hyperresponsiveness and exacerbation.<sup>10-13</sup> MP  
42  
43 pneumonia epidemics are cyclic in 3-4-year intervals, and the duration of an epidemic is  
44  
45 generally limited to 1 year or occasionally 2 years, and during the inter-epidemic period of  
46  
47 the 2-3 years there are a few patients as observed in this study.<sup>14</sup> There are many  
48  
49 asymptomatic healthy MP carriers during the epidemic periods, especially young children,  
50  
51 who may serve as reservoirs for the spread of MP infection.<sup>22-24</sup> It is natural that colonization  
52  
53 of MP during MP pneumonia epidemics can occur in asthma patients and old persons as well  
54  
55 as in healthy young children and adults since colonization does not mean the 'infection'. The  
56  
57 prevalent rates of MP colonization between the asthma group and the control groups could be  
58  
59  
60



1  
2  
3  
4 influenced by the MP epidemic year during the study period. Thus, patient selection bias  
5 could be considered if a study period is long and different in both groups. Wood et al.  
6 reported that the rates of MP colonization in asthmatics and healthy children during the same  
7 study period were similar using a sensitive PCR method,<sup>13</sup> suggesting that colonization occurs  
8 equally in the two groups. One study reported that the status of asthma control and the lung  
9 function tests were not different between asthmatic patients with chronic MP infection and  
10 those without, indicating the similar severity of asthma between the group.<sup>25</sup>

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 In this study, the numbers of patient with RWE during a recent decade did not change with  
22 a rather decreasing trend in recent years. Moreover, we have experienced that asthma severity  
23 might change to a milder phenotype in Korea over time. A recent population-based study in  
24 Korea also indicated that the prevalence of asthma was reduced in recent years.<sup>26</sup> Changing  
25 epidemiology in infectious disease and infection-related immune-mediated diseases,  
26 including scarlet fever, pandemic influenza, acute rheumatic fever, acute post-streptococcal  
27 glomerulonephritis, and Kawasaki disease, has been well documented in Korea; initially  
28 severe disease phenotypes have changed to milder phenotypes over time.<sup>27-30</sup> Because allergic  
29 diseases, including asthma, may be associated with various pathogen infections and  
30 environmental factors,<sup>31,32</sup> it is possible that the changing epidemiology of childhood asthma  
31 occurs over time in the populations.

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
There are some limitations to this retrospective study. We evaluated only admitted patient  
groups with a part of the follow-up subjects at a single hospital. History of allergic diseases  
was not as precise as in International Study of Asthma and Allergies in Childhood (ISAAC)  
studies. In our definition of RWE in the present study, the pneumonia patients with first  
wheezing, regardless of severity of respiratory symptoms, were not included in the asthma  
group. Considering the age distribution of patients, larger part of patients might be the  
transient recurrent wheezers and small part of true asthma patients who experience and

1  
2  
3  
4 progress recurrent wheezing into adulthood might be included in the RWE group. Further  
5  
6 multicenter studies with prospective designs are needed for exact epidemiological  
7  
8 relationship between MP infection and childhood asthma.  
9

10  
11 In conclusions, a small part of MP pneumonia patients had a subsequent wheezing after  
12  
13 initial MP infection as well as those observed in other respiratory pathogen infections.  
14  
15 Patients with RWE have a greater likelihood of experiencing wheezing than non-asthmatics  
16  
17 when they had an initial MP infection, suggesting that MP infection is one of exacerbation  
18  
19 factors in childhood asthma. However, we found no corresponding increase in the number of  
20  
21 patients with RWE in MP pneumonia epidemic periods, and this finding may in part be  
22  
23 explained that MP reinfection are very rare in children including patients with RWE or  
24  
25 asthma as shown in this study.  
26  
27  
28  
29  
30  
31

### 32 **Acknowledgements**

33  
34 The authors thank Drs. Eun-Kyung Kim, Sung-Churl Lee and other colleagues for help in  
35  
36 data collection during study period.  
37  
38  
39  
40

### 41 **Contributors**

42  
43 KYL designed and conceptualized and the study, and drafted the manuscript. JUR  
44  
45 participated in preliminary data collection, and wrote the initial manuscript. HMK and EAY  
46  
47 analyzed data and revised the manuscript for critical content. All authors approved the final  
48  
49 manuscript as submitted and agree to be accountable for all aspects of the work.  
50  
51

### 52 **Funding statement**

53  
54 This research received no specific grant from any funding agency in the public, commercial  
55  
56 or not-for-profit sectors.  
57  
58

### 59 **Competing interests**

None declared.

### Ethic approval

The study was approved by the Institutional Review Board of The Catholic University of Korea Daejeon St. Mary's Hospital (DC17RESI0053).

### Data sharing statement

Data available from the Dryad Digital Repository: <https://doi.org/10.5061/dryad.3kt7fc2>

### REFERENCES

1. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of *Mycoplasma pneumoniae* infections. *FEMS Microbiol Rev* 2008;32:956-73.
2. Lee KY. Pediatric respiratory infections by *Mycoplasma pneumoniae*. *Expert Rev Anti Infect Ther* 2008;6:509-21.
3. Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from an epidemiological approach. *Paediatr Respir Rev* 2004;5:155-61.
4. Strina A, Barreto ML, Cooper PJ, *et al*. Risk factors for non-atopic asthma/wheeze in children and adolescents: a systematic review. *Emerg Themes Epidemiol* 2014;11:5.
5. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998;351:1225-32.
6. Asher MI, Montefort S, Björkstén B, *et al*; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 2006;368:733-43.
7. Johnston SL, Pattemore PK, Sanderson G, *et al*. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995;310:1225-9.

- 1  
2  
3  
4 8. Biscardi S, Lorrot M, Marc E, *et al.* *Mycoplasma pneumoniae* and asthma in children.  
5  
6 *Clin Infect Dis* 2004;38:1341-6.  
7
- 8  
9 9. Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of  
10  
11 asthma. *Expert Rev Respir Med* 2010;4:71-83.  
12
- 13  
14 10. Kraft M, Cassell GH, Henson JE, *et al.* Detection of *Mycoplasma pneumoniae* in the  
15  
16 airways of adults with chronic asthma. *Am J Respir Crit Care Med* 1998;158:998-1001.  
17
- 18  
19 11. Sutherland ER, King TS, Icitovic N, *et al.*; National Heart, Lung and Blood Institute's  
20  
21 Asthma Clinical Research Network. A trial of clarithromycin for the treatment of  
22  
23 suboptimally controlled asthma. *J Allergy Clin Immunol* 2010;126:747-53.  
24
- 25  
26 12. Varshney AK, Chaudhry R, Saharan S, *et al.* Association of *Mycoplasma pneumoniae*  
27  
28 and asthma among Indian children. *FEMS Immunol Med Microbiol* 2009;56:25-31.  
29
- 30  
31 13. Wood PR, Hill VL, Burks ML, *et al.* *Mycoplasma pneumoniae* in children with acute  
32  
33 and refractory asthma. *Ann Allergy Asthma Immunol* 2013;110:328-34.  
34
- 35  
36 14. Kim EK, Youn YS, Rhim JW, *et al.* Epidemiological comparison of three *Mycoplasma*  
37  
38 *pneumoniae* pneumonia epidemics in a single hospital over 10 years. *Korean J Pediatr*  
39  
40 2015;58:172-7.  
41
- 42  
43 15. Lee SC, Youn YS, Rhim JW, *et al.* Early serologic diagnosis of *Mycoplasma pneumoniae*  
44  
45 pneumonia: an observational study on changes in titers of specific-IgM antibodies and  
46  
47 cold agglutinins. *Medicine* 2016;95:e3605.  
48
- 49  
50 16. Papaetis GS, Anastasakou E, Tselou T, *et al.* Serological evidence of *Mycoplasma*  
51  
52 *pneumoniae* infection in patients with acute exacerbation of COPD: analysis of 100  
53  
54 hospitalizations. *Adv Med Sci* 2010;55:235-241.  
55
- 56  
57 17. Lee SI. Prevalence of childhood asthma in Korea: international study of asthma and  
58  
59 allergies in childhood. *Allergy Asthma Immunol Res* 2010;2:61-4.  
60

- 1  
2  
3  
4 18. Lee JH, Han KD, Kim KM, *et al.* Prevalence of atopic dermatitis in Korean children  
5  
6 based on data from the 2008-2011 Korean National Health and Nutrition Examination  
7  
8 Survey. *Allergy Asthma Immunol Res* 2016;8:79-83.  
9
- 10  
11 19. Bacharier LB, Cohen R, Schweiger T, *et al.* Determinants of asthma after severe  
12  
13 respiratory syncytial virus bronchiolitis. *J Allergy Clin Immunol* 2012;130:91-100.  
14
- 15  
16 20. Jackson DJ, Gangnon RE, Evans MD, *et al.* Wheezing rhinovirus illnesses in early life  
17  
18 predict asthma development in high-risk children. *Am J Respir Crit Care Med*  
19  
20 2008;178:667-72.  
21
- 22  
23 21. Kim CK, Chung CY, Kim JS, Kim *et al.* Late abnormal findings on high-resolution  
24  
25 computed tomography after Mycoplasma pneumonia. *Pediatrics* 2000;105:372-378.  
26
- 27  
28 22. Gnarp J, Lundback A, Sundelof B, *et al.* Prevalence of *Mycoplasma pneumoniae* in  
29  
30 subjectively healthy individuals. *Scand J Infect Dis* 1992;24:161-4.  
31
- 32  
33 23. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, *et al.* Results of molecular detection of  
34  
35 *Mycoplasma pneumoniae* among patients with acute respiratory infection and in their  
36  
37 household contacts reveals children as human reservoirs. *J Infect Dis* 2001;183:675-8.  
38
- 39  
40 24. Spuesens EB, Fraaij PL, Visser EG, *et al.* Carriage of *Mycoplasma pneumoniae*  
41  
42 in the upper respiratory tract of symptomatic and asymptomatic children: an  
43  
44 observational study. *PLoS Med* 2013;10:e1001444.  
45
- 46  
47 25. Ansarin K, Abedi S, Ghotaslou R, *et al.* Infection with *Mycoplasma pneumoniae* is not  
48  
49 related to asthma control, asthma severity, and location of airway obstruction. *Int J Gen*  
50  
51 *Med* 2010;4:1-4.  
52
- 53  
54 26. Kim BK, Kim JY, Kang MK, *et al.* Allergies are still on the rise? A 6-year nationwide  
55  
56 population-based study in Korea. *Allergol Int* 2016;65:186-91.  
57  
58  
59  
60

- 1  
2  
3  
4 27. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever,  
5  
6 streptococcal disease, and scarlet fever: the decline of rheumatic fever. *Rev Infect Dis*  
7  
8 1989;11:928-53.  
9  
10  
11 28. Rhim JW, Go EJ, Lee KY, *et al.* Pandemic 2009 H1N1 virus infection in children and  
12  
13 adults: A cohort study at a single hospital throughout the epidemic. *Int Arch Med*  
14  
15 2012;5:13.  
16  
17  
18 29. Keum SW, Hur SM, Youn YS, *et al.* Changes in acute poststreptococcal  
19  
20 glomerulonephritis: an observation study at a single Korean hospital over two decades.  
21  
22 *Child Kidney Dis* 2015;19:112-7.  
23  
24  
25 30. Kil HR, Yu JW, Lee SC, *et al.* Changes in clinical and laboratory features of Kawasaki  
26  
27 disease noted over time in Daejeon, Korea. *Pediatr Rheumatol* 2017;15:60.  
28  
29  
30 31. Atkinson TP. Is asthma an infectious disease? New evidence. *Curr Allergy Asthma Rep*  
31  
32 2013;13:702-9.  
33  
34  
35 32. Hossaini RF, Ghaffari J, Ranjbar A, *et al.* Infections in children with asthma. *J Pediatr*  
36  
37 *Rev* 2013;1:25-36.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Clinical and laboratory findings of the patients with MP pneumonia or recurrent wheezing episode (RWE)**

	MP pneumonia (n = 501)	RWE (n = 384)	<i>P</i>
<b>Clinical characteristics</b>			
Age (y)	5.4 ± 3.4	5.6 ± 3.5	0.31
Male : female	255/246	256/128	<.001
Wheeze at presentation, n (%)	52 (10.4)	384 (100)	<.001
Past history of allergy*, n (%)	72 (14.4)	379 (98.7)	<.001
Past history of wheeze, n (%)	15 (3.0)	384 (100)	<.001
Family history of allergy, n (%)	40 (8.0)	134 (34.9)	<.001
Wheeze after discharge, n (%)	38/180 (21.1)	141/206 (68.4)	<.001
<b>Laboratory findings</b>			
Leukocyte (/ $\mu$ L)	8800 ± 4500	11100 ± 4200	<.001
Eosinophil (%)	2.2 ± 2.9	3.8 ± 3.9	<.001
IgG (mg/dL)	899 ± 235	946 ± 232	<.001
IgE (IU/mL)	267 ± 391	617 ± 673	<.001

\* Number of patients who had history to be diagnosed as having asthma, allergic rhinitis, and/or atopic dermatitis

**Table 2. Clinical and laboratory findings of MP pneumonia patients with wheezing and without wheezing**

	Wheezing (n = 52)	No Wheezing (n = 449)	<i>P</i>
Clinical characteristics			
Age (y)	3.7 ± 3.0	5.6 ± 3.4	<.001
Male : female	32/20	223/226	0.11
Past history of allergy*, n (%)	16 (30.8)	56 (12.5)	0.01
Past history of wheeze, n (%)	10 (19.2)	5 (1.1)	<.001
Family history of allergy, n (%)	8 (15.4)	32 (7.1)	0.05
Wheeze after discharge, n (%)	13/21 (61.9)	25/159 (15.7)	<.001
Laboratory findings			
Leukocyte (x10 <sup>3</sup> //μL)	10400 ± 5400	8700 ± 4.3	0.03
Eosinophil (%)	3.0 ± 3.2	2.1 ± 2.9	0.08
IgG	873 ± 219	903 ± 238	0.43
IgE	407 ± 609	249 ± 350	0.11

\* Number of patients who had history to be diagnosed as having asthma, allergic rhinitis, and/or atopic dermatitis



1  
2  
3  
4 **Figure legends**  
5

6 Figure 1. Flow diagram of the patient selection in this study  
7

8 Figure 2. Annual cases of MP pneumonia and recurrent wheezing episode during 2003-2014  
9

10 Figure 3. Age distribution in MP pneumonia and recurrent wheezing episode groups  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1. Flow diagram of the patient selection in this study

254x190mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig. 2. Annual cases of MP pneumonia and recurrent wheezing episode during 2003-2014  
254x190mm (96 x 96 DPI)




Fig. 3. Age distribution in MP pneumonia and recurrent wheezing episode groups

254x190mm (96 x 96 DPI)

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P4
Objectives	3	State specific objectives, including any pre-specified hypotheses	P4-5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	P5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	P5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P5
Bias	9	Describe any efforts to address potential sources of bias	P5
Study size	10	Explain how the study size was arrived at	P5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P6
		(b) Describe any methods used to examine subgroups and interactions	P6
		(c) Explain how missing data were addressed	-
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	-

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P6
		(b) Give reasons for non-participation at each stage	P6
		(c) Consider use of a flow diagram	P6 (figure 1)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P6
		(b) Indicate number of participants with missing data for each variable of interest	P8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	P8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	-
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	P6-8-
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	-
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P6-8
		(b) Report category boundaries when continuous variables were categorized	P6-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	P8-9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	p11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	P8-11
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P12

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).